ECSP10010695A - Compuestos de piridina - Google Patents

Compuestos de piridina

Info

Publication number
ECSP10010695A
ECSP10010695A EC2010010695A ECSP10010695A ECSP10010695A EC SP10010695 A ECSP10010695 A EC SP10010695A EC 2010010695 A EC2010010695 A EC 2010010695A EC SP10010695 A ECSP10010695 A EC SP10010695A EC SP10010695 A ECSP10010695 A EC SP10010695A
Authority
EC
Ecuador
Prior art keywords
compounds
medicaments
piridine
piridine compounds
humans
Prior art date
Application number
EC2010010695A
Other languages
English (en)
Inventor
Kevin Michael Foote
Bernard Christophe Barlaam
Clifford David Jones
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP10010695A publication Critical patent/ECSP10010695A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con compuestos que inhiben la función de la quinasa de adhesión focal, con los procesos para prepararlos, las composiciones farmacéuticas que los contienen como ingrediente activo, su uso como medicamentos y su uso en la fabricación de medicamentos para tratar enfermedades como el cáncer en animales de sangre caliente como el ser humano.
EC2010010695A 2008-06-17 2010-12-17 Compuestos de piridina ECSP10010695A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7305508P 2008-06-17 2008-06-17

Publications (1)

Publication Number Publication Date
ECSP10010695A true ECSP10010695A (es) 2011-01-31

Family

ID=40896110

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010695A ECSP10010695A (es) 2008-06-17 2010-12-17 Compuestos de piridina

Country Status (17)

Country Link
US (1) US8569298B2 (es)
EP (1) EP2303861B1 (es)
JP (1) JP5551689B2 (es)
KR (1) KR101695501B1 (es)
CN (1) CN102124000B (es)
AU (1) AU2009261764B2 (es)
BR (1) BRPI0914927B8 (es)
CA (1) CA2726508C (es)
CR (1) CR11854A (es)
DO (1) DOP2010000390A (es)
EA (1) EA020807B1 (es)
EC (1) ECSP10010695A (es)
ES (1) ES2472323T3 (es)
IL (1) IL209727A0 (es)
MX (1) MX2010014057A (es)
WO (1) WO2009153589A1 (es)
ZA (1) ZA201100388B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3384482B2 (ja) 1997-03-18 2003-03-10 本田技研工業株式会社 ピストンリング供給装置
US20140155410A1 (en) * 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
WO2010068947A2 (en) * 2008-12-12 2010-06-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Nuclear export inhibitors of topoisomerase ii alpha
PT2464645T (pt) 2009-07-27 2017-10-11 Gilead Sciences Inc Compostos heterocíclicos fusionados como moduladores do canal de iões
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
EP2588081A4 (en) 2010-06-29 2014-12-10 Verastem Inc ORAL FORMULATION OF CHINESE INHIBITORS
MX343894B (es) * 2010-06-30 2016-11-28 Poniard Pharmaceuticals Inc * Síntesis y uso de inhibidores de cinasa.
WO2012003392A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2012103276A1 (en) * 2011-01-26 2012-08-02 Glaxo Wellcome Manufacturing Pte Ltd Combinations
US20130324532A1 (en) 2011-02-17 2013-12-05 Cancer Therapeutics Crc Pty Limited Fak inhibitors
AU2012216894B2 (en) 2011-02-17 2016-07-14 Cancer Therapeutics Crc Pty Limited Selective FAK inhibitors
JP5886411B2 (ja) 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ 新規のピリミジン誘導体
AU2012253653A1 (en) 2011-05-10 2013-05-02 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
TW201341367A (zh) 2012-03-16 2013-10-16 Axikin Pharmaceuticals Inc ３，５－二胺基吡唑激酶抑制劑
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
AP2016009605A0 (en) * 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
US9442005B2 (en) 2014-07-30 2016-09-13 Corning Optical Communications LLC Non-contact methods of measuring insertion loss in optical fiber connectors
HUE049801T2 (hu) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopirazol kináz inhibitorok
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
IL256652B2 (en) 2015-06-29 2026-03-01 Verastem Inc Dapatinib in combination with an anti-PD1 antibody, anti-PDL1 antibody, or anti-PD1 ligand for use in the treatment of cancer
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
PE20211754A1 (es) 2018-02-28 2021-09-06 Basf Se Uso de compuestos de alcoxi pirazol funcionalizados con n como inhibidores de la nitrificacion
WO2019166558A1 (en) 2018-02-28 2019-09-06 Basf Se Use of pyrazole propargyl ethers as nitrification inhibitors
CN112218658A (zh) 2018-03-12 2021-01-12 国家健康科学研究所 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
CN108912095B (zh) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 苯并咪唑类化合物及其制备方法和应用
JP2022525186A (ja) * 2019-03-15 2022-05-11 ザ ジェネラル ホスピタル コーポレイション Ｔｅａｄ転写因子新規小分子阻害剤
EP4045485A1 (en) 2019-10-18 2022-08-24 The Regents Of The University Of California 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders
US12590298B2 (en) 2019-10-18 2026-03-31 The Regents Of The University Of California Ex vivo tumor angiogenesis model
EP4341248A1 (en) 2021-05-21 2024-03-27 Basf Se Use of an n-functionalized alkoxy pyrazole compound as nitrification inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
DE10336184A1 (de) 2003-08-07 2005-02-24 Bayer Materialscience Ag Neue Katalysatoren für die selektive Isocyanatdimerisierung
TWI378923B (en) * 2003-08-15 2012-12-11 Novartis Ag Pyrimidine derivatives
US20090118316A1 (en) 2004-06-21 2009-05-07 Pfzer Inc. Methods for Augmenting Bone
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419160D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
CA2590110C (en) 2004-12-30 2014-06-03 Exelixis, Inc. Kinase modulators and method of use
WO2007063384A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
RS20080272A (sr) 2005-12-21 2009-07-15 Pfizer Products Inc., Derivati pirimidina za tretman neprirodnog rasta ćelija
WO2008073687A2 (en) 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2681015C (en) * 2007-03-16 2016-06-21 The Scripps Research Institute Inhibitors of focal adhesion kinase
US20100190777A1 (en) * 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US20100317663A1 (en) * 2008-02-19 2010-12-16 Jerry Leroy Adams Anilinopyridines as inhibitors of fak

Also Published As

Publication number Publication date
ES2472323T3 (es) 2014-06-30
KR101695501B1 (ko) 2017-01-11
IL209727A0 (en) 2011-02-28
BRPI0914927B8 (pt) 2021-05-25
US20110166139A1 (en) 2011-07-07
EA020807B1 (ru) 2015-01-30
CA2726508C (en) 2016-06-07
CN102124000A (zh) 2011-07-13
CR11854A (es) 2011-02-25
BRPI0914927A2 (pt) 2017-06-20
DOP2010000390A (es) 2011-01-15
WO2009153589A1 (en) 2009-12-23
EP2303861B1 (en) 2014-04-23
KR20110023884A (ko) 2011-03-08
US8569298B2 (en) 2013-10-29
AU2009261764A1 (en) 2009-12-23
BRPI0914927B1 (pt) 2020-10-06
CN102124000B (zh) 2014-09-17
HK1155170A1 (en) 2012-05-11
JP5551689B2 (ja) 2014-07-16
MX2010014057A (es) 2011-03-21
AU2009261764B2 (en) 2013-01-10
CA2726508A1 (en) 2009-12-23
JP2011524411A (ja) 2011-09-01
EA201100032A1 (ru) 2012-01-30
ZA201100388B (en) 2011-10-26
EP2303861A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
CR11854A (es) Compuestos de piridina
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
NI201300041A (es) Antagonistas de mdm2 de espiro-oxindol
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
UY30282A1 (es) Compuestos quimicos
CR20110610A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
UY33890A (es) Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
GT201200147A (es) Antagonistas de espiro-oxindol de mdm2
CR11641A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
ECSP099451A (es) Compuestos de urea policíclicos antibacterianos
CO6640285A2 (es) 5-alquinil-pirimidinas
UY32383A (es) Dionas cíclicas herbicidamente activas, derivados, procesos para su preparación composiciones que las comprenden y usos de las mismas
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
CU20120042A7 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
DOP2015000170A (es) Compuestos químicos
UY30544A1 (es) Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones
UY31141A1 (es) Compuestos de piperidina y sus usos
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
DOP2010000374A (es) Derivados heterociclicos de la urea y sus metodos de empleo
CR11825A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas